Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum 299 + lactobacillus plantarum 299v
- Development stage
- Unknown
- Lead developer
- Probi
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus plantarum* strains 299 and 299v are specific probiotic bacterial strains belonging to the *Lactiplantibacillus plantarum* species. These strains are recognized for their robust ability to survive gastric acidity, adhere to the human intestinal mucosa, and promote a healthy gut microbiome. In clinical research, particularly in the context of allogeneic hematopoietic stem cell transplantation (HSCT), this combination is being evaluated for its potential to maintain intestinal barrier integrity and prevent the translocation of pathogens into the bloodstream. By modulating the gut environment and immune response, these strains aim to reduce the incidence of life-threatening complications such as bacteremia and acute graft-versus-host disease (GVHD) in pediatric and adolescent patients.
- Brand names
- Probi DigestisTuZen
- Other names
- L. plantarum 299L. plantarum 299vLactiplantibacillus plantarum 299Lactiplantibacillus plantarum 299v
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on lactobacillus plantarum 299 + lactobacillus plantarum 299v.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum 299 + lactobacillus plantarum 299v.